HZHong Zhou

Hong Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hong Zhou has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Wang

    Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China

    1 shared publication
  • Hui Kong

    Department of Pulmonary & Critical Care Medicine, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, PR China

    1 shared publication
  • Jingjing Wang

    Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, People's Republic of China

    1 shared publication
  • Liyao Peng

    Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, China

    1 shared publication
  • Min Yu

    Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, People's Republic of China

    1 shared publication
  • Mingxia Yang

    Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou 213003, People's Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Global burden of smoking-related COPD in men aged >40 years: A secondary analysis of the Global Burden of Disease 2021 study, 1990–2021 with projections to 2050

    by Hong Zhou, Xinyun Zhao, Yiting He, Wen Huang

    Introduction: Chronic obstructive pulmonary disease (COPD) imposes great threat to public health and social economy. However, the burden of male COPD patients aged >40 years caused by smoking has rarely been reported. The aim of this study is to study the global burden of smoking-related COPD...

  • Open Access

    Paeoniflorin Ameliorates Chronic Hypoxia/SU5416-Induced Pulmonary Arterial Hypertension by Inhibiting Endothelial-to-Mesenchymal Transition

    by Min Yu, Liyao Peng, Ping Liu, Mingxia Yang, Hong Zhou, Yirui Ding, Jingjing Wang, Wen Huang, Qi Tan, Yanli Wang, et al.

    Background: Endothelial cells dysfunction is one of the hallmark pathogenic features of pulmonary arterial hypertension (PAH). Paeoniflorin (PF) is a monoterpene glycoside with endothelial protection, vasodilation, antifibrotic, anti–inflammatory and antioxidative properties. However, the effects of PF on PAH remain unknown. Methods: Here, we investigated the efficacy of PF in the SU5416/hypoxia (SuHx) rat model of PAH. Human pulmonary arterial endothelial cells (HPAECs) were exposed to 1% O2 with or without PF treatment. Results: Hemodynamics analysis showed that prophylactic treatment with PF (300 mg/kg i.g. daily for 21 days) significantly inhibited chronic hypoxia/SU5416-induced elevations of right ventricular systolic pressure (RVSP) and right ventricular hypertrophy index in rats. Meanwhile, PF significantly reduced pulmonary vascular remodeling, as well as alleviated collagen deposition in lungs and right ventricles in SuHx rats. Additionally, PF inhibited SuHx–induced down-regulation of endothelial marker (vascular endothelial cadherin) and up-regulation of mesenchymal markers (fibronectin and vimentin) in lung, suggesting that PF could inhibit SuHx–induced endothelial-to-mesenchymal transition (EndMT) in lung. Further in vitro studies confirmed that PF treatment suppressed hypoxia-induced EndMT in HPAECs, which was abolished by the knockdown of bone morphogenetic protein receptor type 2 (BMPR2) in HPAECs. Conclusion: Taken together, our findings suggest that PF ameliorates BMPR2 down-regulation-mediated EndMT and thereafter alleviates SuHx–induced PAH in rats.